Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 301–400 of 809
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Butt, W. Z., & Yee, J. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01013-x · Cited by 13
Du, Z., Li, F., Li, L., Wang, Y., Li, J., Yang, Y., Jiang, L., Wang, L., & Qin, Y. (2022) · iScience · doi:10.1016/j.isci.2022.105334 · Cited by 15
“(Alves et al., 2020; Raal et al., 2020).”
BackgroundMechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 18
Rosenson, R. S., Rader, D. J., Ali, S., Banerjee, P., McGinniss, J., & Pordy, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07567-z · Cited by 13
“Briefly, the phase III ELIPSE HoFH trial comprised patients (≥ 12 years of age) with HoFH on stable LLT (± lipoprotein apheresis) and screening LDL-C ≥ 70 mg/dL [11].”
InfluentialSelf-citationNovel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 15
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Reyes‐Soffer, G. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000619 · Cited by 13
Jiang, S., Ren, Z., Yang, Y., Liu, Q., Zhou, S., & Xiao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115874 · Cited by 15
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
“In patients with HoFH, agents, such as lomi-tapide and evinacumab, which act through alternate bio-chemical pathways, as well as LDL apheresis, have shown superior efficacy [33, 38, 39].”
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 13
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
Malick, W. A., Choi, D., Langsted, A., Bittner, V., Nordestgaard, B. G., Stroes, E. S. G., & Rosenson, R. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf123 · Cited by 15
Self-citationTherapeutic application of genome editing in dyslipidemia
Whittaker, M. N., & Musunuru, K. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000805 · Cited by 12
Evans, P. C., Davidson, S. M., Wojta, J., Bäck, M., Bollini, S., Brittan, M., Catapano, A. L., Chaudhry, B., Cluitmans, M. J. M., Gnecchi, M., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac114 · Cited by 14
2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.213 · Cited by 12
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Homozygous Familial Hypercholesterolemia in Canada
Brown, L., Ruel, I. L., Baass, A. W., Bergeron, J., Brunham, L. R., Cermakova, L., Couture, P., Gaudet, D., Francis, G. A., Hegele, R. A., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100309 · Cited by 13
Self-citationAlonso, R., Arroyo-Olivares, R., Díaz-Díaz, J. L., Fuentes, F. J., Arrieta, F., de Andrés, R., González‐Bustos, P., Argüeso, R., Martín-Ordiales, M., Faedo, C. M., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117516 · Cited by 18
Approach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 13
Hammad, M. M., Channanath, A. M., Abu‐Farha, M., Rahman, A., Khairi, I. A., Cherian, P., Alramah, T., Alam-Eldin, N., Al‐Mulla, F., Thanaraj, T. A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1314211 · Cited by 11
“The focal action of leptin in hypothalamic neurons leads to decreased caloric intake and raises energetic expenditure in the long-term (46).”
BackgroundResultTanigawa, R., Nakajima, A., Eguchi, Y., Takahashi, H., Loomba, R. S., Suganami, H., Tanahashi, M., Saito, A., Iida, Y., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65395 · Cited by 11
Arca, M., D’Erasmo, L., Cuchel, M., Blom, D. J., Cegla, J., Duell, P. B., Santos, R. D., & O’Brien, S. L. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.015 · Cited by 19
Wilkinson, M. J., Bijlani, P., Davidson, M., Duell, P. B., Horan, M., Malloy, M. J., Newfield, R. S., Pradeep, P., Shah, P. K., Stock, E. O., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322364 · Cited by 13
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
“C by nearly 50% in patients with HoFH beyond existing lipid‑lowering therapies (NCT no. 03399786) (199).”
Ho, V. Q. T., Tran, N. B., Nguyen, N. M. T., Arrighini, G. S., Downes, D., Dandamudi, M., Ferrara, V. Z., Ho, T. H. Q., Walia, H., Barbagelata, A., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003490 · Cited by 12
Advances in the care of lipodystrophies
Shamsudeen, I., & Hegele, R. A. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000695 · Cited by 11
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 12
“Thereafter, a phase 3 double blind placebo-controlled trial was designed to assess the percent change in LDL-C from baseline to 24 weeks of follow-up [69].”
BackgroundKraaijenhof, J. M., Tromp, T. R., Nurmohamed, N. S., Reeskamp, L. F., Langenkamp, M., Levels, J. H. M., Boekholdt, S. M., Wareham, N. J., Hoekstra, M., Stroes, E. S. G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030476 · Cited by 14
“13 The latter finding suggests that the lipid-lowering property of ANGPTL3 inhibition is independent of the functioning of the LDL receptor, 14 providing a therapeutic option in those patients with severely reduced or even absent LDL receptor functioning.”
BackgroundSelf-citationInteraction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications
Zubirán, R., Cruz‐Bautista, I., & Aguilar-Salinas, C. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01626-2 · Cited by 13
“In the ELIPSE HoFH trial [115], an intravenous infusion of evinacumab 15 mg/kg every 4 weeks ( n = 42) showed a 47% reduction in LDL‑”
MethodTreatment of Homozygous Familial Hypercholesterolemia With Evinacumab
Jeraj, N., Huang, S. S., Kennedy, B. A., & Hegele, R. A. (2021) · CJC Open · doi:10.1016/j.cjco.2021.11.009 · Cited by 11
“A recent 24-week study of evinacumab in HoFH patients revealed significant reductions in LDL-C levels.(5) Although the mechanism of ANGPTL3 inhibition and LDL-C level reduction is incompletely understood, it must be partially independent of LDL receptor activity because of its efficacy in HoFH patients.”
BackgroundANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
Chen, J., Luo, Q., Yi, Y., Wang, J., Chen, P., Luo, F., & Fang, Z. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02352-1 · Cited by 12
“Inhibition of ANGPTL3 can significantly reduce TG-rich lipoprotein and LDL cholesterol and improve HDL-mediated reverse cholesterol transport in mice [6, 25, 56].”
BackgroundInfluentialSánchez-Hernández, R. M., Ibarretxe, D., Fuentes, F. J., Martínez‐Hervás, S., Blanco-Echevarría, A., Rodríguez, B. C., Rodríguez-Carnero, G., Ordiales, M. M. M., Pérez, A., González‐Bustos, P., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae784 · Cited by 11
Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction
Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1727918 · Cited by 12
Evinacumab for the treatment of homozygous familial hypercholesterolemia
Gao, Y.-L., Zhang, B., & Yang, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2047934 · Cited by 10
Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11
“Several targets involved in lipid metabolism are already popular for lipidregulating therapies, such as HMGCR (statins), NPC1L1 (ezetimibe), PCSK9 (alirocumab, evolocumab, inclisiran), and ANGPTL3 (evinacumab) (Raal et al., 2020b).”
Background2022 Consensus statement on the management of familial hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., on behalf of Task Force Team for Familial Hypercholesterolemia, & Korean Society of Lipid and Atherosclerosis (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.121 · Cited by 13
“Because the exposure of vessels of patients with HoFH to lipids is more severe than that of patients with HeFH, the incidence of CAD under the age of 20 is not uncommon.”
BackgroundInfluentialDuell, P. B., & Warden, B. A. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13856 · Cited by 10
“The authors incorrectly stated that only 7% met US criteria for apheresis) [10].”
BackgroundInfluentialMorinaga, J., Kashiwabara, K., Torigoe, D., Okadome, Y., Aizawa, K., Uemura, K., Kurashima, A., Matsunaga, E., Fukami, H., Horiguchi, H., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318880 · Cited by 10
Gu, J., Kuznik, A., Quon, P., Chauhan, A., Sravya, T. S., & Raal, F. J. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad203 · Cited by 10
Self-citationTailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies
Dankar, R., Wehbi, J., & Refaat, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040461 · Cited by 11
“After 24 weeks, patients in the evinacumab group had a 47.1% relative decrease from baseline in the LDL-c level, whereas the placebo group’s LDL-c level increased by 1.9% [14].”
BackgroundInfluentialWright, J., & Subramanian, S. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.005 · Cited by 12
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia
Damase, T. R., Sukhovershin, R. A., Godin, B., Nasir, K., & Cooke, J. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067957 · Cited by 11
Ibi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R. W., Rensen, P. C. N., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.015 · Cited by 10
“…were treated for 24 weeks with the Angiopoietin-like 3 protein inhibitor Evinacumab, to enhance LPL-mediated TRL clearance, on top of classical LDL-C-lowering therapy, showed a 47.1% reduction in LDL-C levels compared with a 1.9% increase in the group who received only lipid-lowering therapy [11].”
InfluentialRole of Genetics in Preventive Cardiology: Focused on Dyslipidemia
Lee, S. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0239 · Cited by 10
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
“Evinacumab displays antiatherogenic activity in rodents [13, 22], and potent and consistent TG and LDL-C lowering effects (by 40% in healthy volunteers [23] and up to 49% in participants with homozygous FH [24]).”
BackgroundFornari, E., Stefanutti, C., Mancioppi, V., Watts, G. F., Pisciotta, L., Morandi, A., & Maffeis, C. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.012 · Cited by 9
Fusco, S. A. D., Volpe, M., Nardi, F., Matteucci, A., Aquilani, S., Marino, G., Aiello, A., & Colivicchi, F. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00708-x · Cited by 13
“The recognition that these variants were associated with low LDL-C and were protective against ASCVD has led to the development of therapeutic approaches targeting ANGPTL3 [35].”
de Gier, C., Neyer, M., Draxler-Dworzak, S., Baumgartner-Kaut, M., Müller-Sacherer, T., Arbeiter, K., & Greber‐Platzer, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119234 · Cited by 9
Yang, Y., Lorincz‐Comi, N. J., Li, M., & Zhu, X. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf250 · Cited by 12
Management of Mild-to-Moderate Hypertriglyceridemia
Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 12
Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
Krzemińska, J., Młynarska, E., Radzioch, E., Wronka, M., Rysz, J., & Franczyk, B. (2022) · Biomedicines · doi:10.3390/biomedicines10123273 · Cited by 9
“Incidental cases involved the occurrence of suicide attempt, urosepsis, and anaphylactic reaction [13,68].”
BackgroundMethodInfluentialFamilial Hypercholesterolemia in Children. The Current State of the Problem
Sadykova, D. I., Salakhova, K. R., Галимова, Л. Ф., Сластникова, Е. С., & Данилевна, Х. Ч. (2023) · Вопросы современной педиатрии · doi:10.15690/vsp.v22i3.2576 · Cited by 10
Watts, G. F., & Chan, D. C. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1484 · Cited by 10
Alshahrani, A. S., Kholaif, N., Al-Khnifsawi, M., ZARIF, H. A., & Mahzari, M. M. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02764-y · Cited by 11
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
“Like other intravenously administered drugs, evinacumab has the potential to cause severe allergic reactions or even anaphylaxis [72].”
BackgroundWatts, G. F., Zadeh, S. S. T., & Chan, D. C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae321 · Cited by 9
Navigating Lipodystrophy: Insights from Laminopathies and Beyond
Krüger, P., Hartinger, R., & Djabali, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158020 · Cited by 11
“In a clinical trial, patients with homozygous familial hypercholesterolemia treated with evinacumab showed a 47% reduction in LDL levels compared to a placebo group [221] (Table 2).”
BackgroundEffects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
Zhang, L., Li, B., Chen, W., Li, W., Yang, H., & Pan, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25248 · Cited by 11
Pu, X., Sale, M. E., Yang, F., Zhang, Y., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12711 · Cited by 10
Self-citationGutiérrez-Castro, K. P., González, A. P., Caccavello, R. J., Garay‐Sevilla, M. E., & Gugliucci, A. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.016 · Cited by 9
Chaudhry, A., Trinder, M., Vesely, K., Cermakova, L., Jackson, L. M., Wang, J., Hegele, R. A., & Brunham, L. R. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003887 · Cited by 9
Evolving ANGPTL-based lipid-lowering strategies and beyond
Ng, D. S. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000764 · Cited by 9
Bypassing the LDL Receptor in Familial Hypercholesterolemia
Kersten, S. (2020) · New England Journal of Medicine · doi:10.1056/nejme2023520 · Cited by 9
Santos, R. D., & Cuchel, M. (2024) · Circulation · doi:10.1161/circulationaha.123.067241 · Cited by 9
Therapeutic Gene Editing in Dyslipidemias
Zadeh, S. S. T., & Shapiro, M. D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508286 · Cited by 9
“It follows an autosomal dominant inheritance pattern andis characterized by tendinous xanthomas, arcus juvenilis, and premature coronary heart disease (CHD) [27].”
BackgroundWang, Y., Choe, J. Y. S., Shi, Y., Thi, T. T., Cao, X., Hu, Y., Cheng, K. Y., Li, H., Ji, Y., Liu, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202412677 · Cited by 8
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis
Fukami, H., & Oike, Y. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22038 · Cited by 10
“Importantly, these patients had previously undergone intensive treatment with lipid-lowering therapies such as high-dose statins, ezetimibe, and PCSK9 inhibitors 15) , demonstrating that evinacumab has an additive lipid-lowering effect in patients receiving these standard therapies.”
Das, V., Narayanan, S., Zhang, X., Bergman, O., Djordjevic, D., Kronqvist, M., Chemaly, M., Karadimou, G., Sundman, S., Prasad, I., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01601-5 · Cited by 8
“Clinical studies in patients with different forms of dyslipidemia have demonstrated that inactivation of ANGPTL3 using monoclonal antibodies (evinacumab) or antisense oligo-nucleotides markedly lowers plasma LDL and TG levels [50].”
Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2021.200107 · Cited by 8
Childhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil, B., & Ashraf, A. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01000-2 · Cited by 9
Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease
Mszar, R., Webb, G., Kulkarni, V., Ahmad, Z., & Soffer, D. E. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.009 · Cited by 9
Lv, Q., Jiao, X., Yu, H., Sun, Q., Fan, L., Wang, Y., Sun, H., Du, Z., Li, L., Hu, C., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025955 · Cited by 9
“43 Considering the strong causal relationship between plasma ANGPTL3 and CAD risk, treatment modalities targeting ANGPTL3 are recently emerging in preclinical and clinical trials, so the plasma ANGPTL3 may play the important prediction value independent of plasma lipid levels in the future.”
New Trends and Therapies for Familial Hypercholesterolemia
Alnouri, F., & Santos, R. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226638 · Cited by 8
“Loss-of-function variants of the ANGPTL3 gene are associated with lower serum cholesterol and triglyceride levels and a lower ASCVD risk [77].”
BackgroundInfluentialSerum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease
Rodríguez-Hernández, O., Palau, M. C., Hernández-Camba, A., Alonso-Abreu, I., Ramos, L., de Armas‐Rillo, L., Martín‐González, C., López‐Mejías, R., González-Gay, M. Á., & Ferraz‐Amaro, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065194 · Cited by 10
“For example, evinacumab and vupanorsen (angiopoietinlike protein 3 inhibitors) and olezarsen (an antisense oligonucleotide-targeting apolipoprotein C-III) have shown efficacy in reducing LDL cholesterol [22,23], and studies are being carried out to define their effect in CV disease and CV events.”
BackgroundSviridov, D. O., Dasseux, A., Reimund, M., Pryor, M., Drake, S. K., Jarin, Z., Wolska, A. T., Pastor, R. W., & Remaley, A. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1223920 · Cited by 9
“Another interesting possibility is that ApoC2 mimetic peptides may also counter the anti-lipolytic effects of ANGPLT3/8, an already established therapeutic target that have shown great effect in lowering LDL-C and ApoB even in Familial Hypercholesterolemia patients (93, 94).”
BackgroundFamilial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment
Arnold, N., & Köenig, W. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2408236 · Cited by 15
“Approximately 50% LDL-C reduction under evinacumab therapy has been demonstrated in HoFH subjects and those with refractory hypercholesterolemia [99,100].”
BackgroundSrivastava, R. A. K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.010 · Cited by 8
Chen, H., Tang, X., Su, W., Li, S., Yang, R., Cheng, H., Zhang, G., & Zhou, X. (2023) · Aging · doi:10.18632/aging.205347 · Cited by 10
“…subtilisin/kexin type 9 ( PCSK9 ) inhibitors, and bempedoic acid ( BA ) are several newer nonstatin medications with cholesterol-lowering effects [7, 8], while angiopoietin-like protein 3 ( ANGPTL3 ) inhibitors and antisense oligo-nucleotides targeting the mRNA of apoprotein C-III ( APOC3…”
Rossi, I., Marodin, G., Lupo, M. G., Adorni, M. P., Papotti, B., Dall’Acqua, S., & Ferri, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073708 · Cited by 10
“Evinacumab is currently approved for the treatment of patients with homozygous familial hypercholesterolemia, regardless of the degree of their LDL-receptor function [13].”
BackgroundEvinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study
Iannuzzo, G., Calcaterra, I. L., Gentile, M., Stanzione, C., Ruberto, F. D., Taranto, M. D. D., Fortunato, G., & Minno, M. N. D. D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03160-4 · Cited by 10
Rached, F. H., & Santos, R. D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01514-2 · Cited by 9
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 12
Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
Mirzai, S., Chevli, P. A., Rikhi, R. R., & Shapiro, M. D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411311 · Cited by 11
“…(ELIPSE HoFH) phase 3 trial compared evinacumab to placebo in patients with HoFH not achieving LDL-C goal despite multiple LLT (77% on statins, 75% ezetimibe, 77% PCSK9 inhibitors, 25% lomitapide, and 34% lipid apheresis) and found a 49% placebo-controlled LDL-C reduction at 24 weeks [86].”
Khoury, É., Croteau, L., Lauzière, A., & Gaudet, D. (2022) · Future Cardiology · doi:10.2217/fca-2021-0149 · Cited by 8
Self-citationQiu, H., Zhang, L., & Zhu, Z. (2022) · Medicina · doi:10.3390/medicina58101430 · Cited by 9
“, alirocumab, evolocumab, and inclisiran) [18–23], and evinacumab [24,25], have been shown to significantly reduce LDL-C levels in adult HoFH patients.”
BackgroundEvinacumab for Homozygous Familial Hypercholesterolemia
Luo, F., Das, A., & Fang, Z. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2033612 · Cited by 8
He, J., Dai, Y., Xu, F., Huang, X., Gao, Y., Liu, L., Zhang, W., & Liu, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140826 · Cited by 8
Treating Cardiovascular Disease with Liver Genome Engineering
Hurley, A. E., & Lagor, W. R. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00986-z · Cited by 7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder
Loh, W. J., & Watts, G. F. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01077-9 · Cited by 9
Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
Shamsudeen, I., McCrindle, B. W., & Hegele, R. A. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad058 · Cited by 8
Tandirerung, F. J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07505-5 · Cited by 7
Novel Pharmacotherapies for Hyperlipidemia
Reamy, B. V., Ford, B., & Goodman, C. (2023) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2023.08.002 · Cited by 7
Emerging agents targeting triglycerides
Prakash, Y. S., Bhatt, D. L., & Malick, W. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000979 · Cited by 7
Grassi, G. M., Pinto, R. D., Rosei, C. A., Agnoletti, D., Borghi, C., Cicero, A. F. G., Ciuceis, C. D., Desideri, G., Grassi, D., Muiesan, M. L., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00501-6 · Cited by 9
“Evinacumab is a fully human monoclonal antibody with inhibitory effect on angiopoietin-like protein 3 (ANGPTL3) [39, 40], the gene of which is predominantly expressed in the liver [41].”
BackgroundInfluentialManaging of dyslipidaemia characterized by accumulation of triglyceride-rich lipoproteins
Visser, J., van Zwol, W., & Kuivenhoven, J. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00979-y · Cited by 7
A stepwise approach to prescribing novel lipid-lowering medications
Kakavand, H., Aghakouchakzadeh, M., Shahi, A., Virani, S. S., Dixon, D. L., Tassell, B. W. V., & Talasaz, A. H. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.003 · Cited by 7
Gene Therapy for Paediatric Homozygous Familial Hypercholesterolaemia
Graves, L. E., Horton, A., Alexander, I. E., & Srinivasan, S. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.01.017 · Cited by 7
Algorithms for Treating Dyslipidemia in Youth
Kim, G. K., Yee, J. K., & Bansal, N. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01122-1 · Cited by 8
Tada, H., Okada, H., Kawashiri, M., & Takamura, M. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102367 · Cited by 7
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.